86.90 +0.38 (0.44%)
After hours: 6:25PM EDT
Previous Close | 84.34 |
Open | 85.58 |
Bid | 84.21 x 900 |
Ask | 86.70 x 800 |
Day's Range | 85.57 - 88.01 |
52 Week Range | 56.19 - 113.06 |
Volume | 84,141 |
Avg. Volume | 133,346 |
Net Assets | 196.28M |
NAV | 84.50 |
PE Ratio (TTM) | N/A |
Yield | 0.00% |
YTD Daily Total Return | -4.88% |
Beta (5Y Monthly) | 1.82 |
Expense Ratio (net) | 0.95% |
Inception Date | 2010-04-06 |
Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.
Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.
Nasdaq Stock Exchange President Nelson Griggs joins Yahoo Finance’s Seana Smith to discuss market operations amid the coronavirus and the outlook on IPOs.